Figure 2 | Leukemia

Figure 2

From: A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

Figure 2

(a) Histological and immunohistochemical (anti-CD138/MI15 (Dako, Dako Itala S.p.A., Milano, Italy), anti-κ (Dako) and anti-λ (Dako)) analysis of retrieved PCLSs. Line 1 shows unselected BMMCs; line 2 shows selected CD138+ on heterologous BMSCs; line 3 shows selected CD138+ from PB of a PCL patient on heterologous BMSCs; and line 4 shows IL-6-dependent INA-6 MM cells on heterologous BMSCs. Anti-human κ-light chains and anti-human λ-light chains were used (Dako). Dilutions were 1:15 000 for κ-light chains and 1:10 000 for λ-light chains. (b) Ki-67 staining of MM-bearing PCLSs retrieved 3–4 months after cell injection. (c, d) Kinetics of appearance of paraproteins in sera from representative SCID-synth-hu mice engrafted with samples from MM patients. A code for each patient sample is provided according to Table 1. Left panel includes seven samples from patients with whole paraprotein (ELISA, GenWay Biotech Inc., San Diego, CA, USA); right panel includes two patients with light chain MM (ELISA, Bethyl Laboratories Inc., Montgomery, TX, USA).

Back to article page